does blue cross cover glp-1 Blue Shield of Mass. sees gains after years of GLP-1-related losses Alberta Blue Cross 2026 Pipeline:

Novo Nordisk has a GLP-1 pill for diabetes, Rybelsus, but its not as effective for weight loss as injectable versions and was never approved for weight management

Severe or persistent side effects warrant immediate provider contact

Future Directions and Research Opportunities Triple Agonism and Beyond The success of dual agonism has stimulated interest in triple agonism approaches that add glucagon receptor activation to GIP and GLP-1 targeting

GLP-1 Pipeline In November 2023, the FDA approved Zepbound (tirzepatide), a GLP-1 antagonist and GIP dual agonist with superior weight loss efficacy compared to its competitors

Tirzepatide, with its dual GLP-1 and GIP action, seems to show the highest weight loss potential, though it is still under evaluation